Pfizer Oncology to present cancer drugs at annual cancer research conference
NEW YORK Presenters from Pfizer’s cancer drugs unit will have a lot of work to do at the annual meeting of the American Association for Cancer Research in Washington this weekend.
Pfizer Oncology announced Wednesday that the company would present data on investigational cancer drugs such as figitumumab, a monoclonal antibody for lung cancer, as well as Sutent (sunitinib) and the kidney cancer drug axitinib, as well as drugs for lymphoma and others.
“Pfizer’s data at AACR demonstrate our strategic focus on the discovery and development of novel mechanisms that align complex biology with creative clinical strategies,” Pfizer Oncology Research Unit chief scientific officer Neil Gibson said. “Our research on the mutations and pathways that are genetic drivers of the segments of disease, defined by specific ‘genetic signatures,’ is designed to help us identify patient populations that will derive the most benefit from the novel therapeutic modalities we discover and develop.”